Merida Biosciences
Michael Naill currently serves as Senior Vice President of Product and Process Development at Merida Biosciences since April 2024. Prior to this role, Michael held multiple positions at Dragonfly Therapeutics, Inc., including Senior Vice President, Vice President, and Senior Director of CMC Technical Operations from May 2018 to March 2024. Earlier experience includes a Director role in Manufacturing Sciences and an Associate Director role in CMC Regulatory Science at bluebird bio and AbbVie, respectively. Michael began professional career as a Senior Scientist in Technical Operations at Abbott Laboratories. Academic qualifications include a Ph.D. in Chemical Engineering from the University of Massachusetts Amherst and a Bachelor of Science in Chemical Engineering from the University of Illinois Urbana-Champaign.
This person is not in any teams
This person is not in any offices
Merida Biosciences
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.